Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

748.01 -1.91 (-0.25%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Missed Out on Eli Lilly? Buy This Amazing Growth Stock Instead
The company expects to enjoy many GLP-1 tailwinds in 2025. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Assessing Eli Lilly's Performance Against Competitors In Pharmaceuticals Industry
Via Benzinga
Is Eli Lilly a Buy? Analyst Confidence Grows for 2025
Eli Lilly's price pullback is an opportunity worth 25%, with analysts' sentiment firming around the $1000 level. New highs are likely by early 2025. 
Via MarketBeat
Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required
A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks. 
Via Talk Markets
Why Eli Lilly Stock Is Sinking Today
The big pharmaceutical company provided a disappointing Q3 update. 
Via The Motley Fool
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG's Treg-focused action as a potential breakthrough for Alopecia areata treatment. 
Via Benzinga
What's Going On With Hims & Hers Health Stock Monday?
Hims & Hers Health will report third-quarter financial results after the market close on Monday. Analysts expect the company to report earnings of 4 cents per share and revenue of $382.2 million,... 
Via Benzinga
As Race To Best 'Miracle' Obesity Drug Heats Up, Ozempic Maker Novo Nordisk Tests New Hybrid Drug That Can Reduce Weight Up To 25%
Novo's development chief, Martin Holst Lange, has shown optimism about the drug's promise, though he refrained from making any guarantees. 
Via Benzinga
Viking Therapeutics Surges, Set To Break Out On Latest Obesity Drug Data
The biotech reported strong weight loss for higher doses of its experimental obesity pill. 
Via Investor's Business Daily
Could This Near Trillion-Dollar Stock Be a Millionaire Maker?
Size means little in light of this company's prospects. 
Via The Motley Fool
Market Volatility Soars Ahead Of Elections, Tech Earnings Mixed, Strikes And Hurricanes Knock Employment Down: This Week In The Markets
The U.S. stock market experienced a setback at the end of October, breaking a five-month winning streak. Are politics to blame? 
Via Benzinga
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water. 
Via Investor's Business Daily
Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
Novo Nordisk's ESSENCE trial of semaglutide 2.4 mg shows significant improvements in liver fibrosis and steatohepatitis outcomes, with regulatory filings planned for 2025. 
Via Benzinga
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip
The market overreacted to Lilly's Q3 earnings miss and full-year guidance cut. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
Viking Therapeutics Stock: A Pre-Election Bet Worth Considering
Viking Therapeutics is making headway in the weight loss drug market; but even though the payoff is years away, there's still plenty of upside for investors 
Via MarketBeat
Nasdaq Tumbles Over 100 Points Ahead Of Big Tech Earnings: Fear & Greed Index Remains In 'Greed' Zone
Via Benzinga
Are Eli Lilly's Lowered Expectations a Reason to Sell?
Accounting for an acquisition Eli Lilly completed in August made a big impact on earnings expectations for 2024. 
Via The Motley Fool
Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO
The company expects to have topline results from a Phase 2 study later this year. 
Via Investor's Business Daily
AMD Earnings Show Power Of Nvidia Software, ADP Data Defies Expectations
To gain an edge, this is what you need to know today. 
Via Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
Via Benzinga
Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast
Via Benzinga
Exposures Fossil Fuels
Eli Lilly (LLY) Q3 2024 Earnings Call Transcript
LLY earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Wall Street Mixed, Semiconductors Tumble As AMD Disappoints, Alphabet Rallies, SMCI Plummets: What's Driving Markets Wednesday?
Wall Street experienced a mixed trading session on Wednesday as investors weigh a batch of corporate earnings and fresh economic data. 
Via Benzinga
Eli Lilly CEO David Ricks On Q3 Results: The Underlying Growth Story Is Fantastic
Eli Lilly reported its latest quarterly earnings. 
Via Talk Markets
O-I Glass Posts Downbeat Results, Joins AMD, Qorvo And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Eli Lilly Q3 Earnings: Mounjaro Sales More Than Double, Takes $2.98 Billion Hit To Profit, Cuts Annual Outlook, Stock Tanks
Eli Lilly's stock falls as Q3 earnings miss estimates. 2024 guidance lowered due to IPR&D costs. 
Via Benzinga
Topics Earnings
Exposures Financial
Eli Lilly Dives On Earnings Miss As Diabetes, Weight-Loss Drugs Fall Short
The pharma giant blamed "inventory decreases in the wholesaler channel." 
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Zepbound, Mounjaro Maker Eli Lilly Climbs In Wednesday Pre-Market As Impressive 51% YTD Gain Sparks Stock Split Speculation
Its products Mounjaro and Zepbound generating over $4 billion in the last quarter. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.